NOYADA (captopril), converting enzyme inhibitors

High clinical benefit for arterial hypertension, heart failure, myocardial infarction and diabetic nephropathy of type I diabetes, but no proven clinical added value compared to other converting enzyme inhibitors already available in solid form

• NOYADA has been granted a marketing authorisation for the treatment of arterial hypertension, heart failure, myocardial infarction and diabetic nephropathy of type I diabetes.

• It consists of a new dosage form of captopril in oral solution, suitable for paediatric use and for adults with swallowing disorders.

• In paediatrics, it should replace the crushing of tablets or compounding by pharmacies for in-house use in paediatrics.